The Australian Centre for Disease Control (CDC) is seeking submissions for a pilot human biomonitoring study to assess human exposure to harmful chemicals, including PFAS. The project is expected to run for approximately 12 months, with a proposed start date of April 27, 2026. The closing date for the ATM is February 25, 2026. The study involves sample collection, laboratory analysis, and reporting. The evaluation criteria include the service provider's understanding of the services required, capability, capacity, relevant experience, and value for money. The contract will incorporate the Commonwealth contract terms. Questions are permitted until February 20, 2026.
The pilot study is expected to run for approximately 12 months. The pilot study is expected to run for approximately 12 months.
The parties agree to use the paneuropean public procurement online framework for electronic invoicing for this contract, 5 calendar days or otherwise, 20 calendar days.
Submissions will be evaluated against criteria as per the commonwealth ATM terms, clause a. b. 5. he extent to which the potential suppliers response meets the customers requirement set out in the atm
The successful applicant is expected to have the relevant skills, experience and capacity to support key components of the study, including but not limited to: sample collection, laboratory analysis, data management, reporting, and project management.
Unless otherwise notified by an addendum, there are no site inspections for this ATM.
Questions will be permitted up until 5:00 pm Friday, 20 February 2026, ACT local time.